RxDoctor Payments Data

Tejaskumar Shah

Interventional Cardiology · Rock Hill, SCNPI 1871721076

Payments from drug & device makers

$7,053in general payments, 2019–2025

Across 169 payments — averaging $41.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Edwards Lifesciences$750
  • Abbott$609
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$291
  • Merck$287
  • Teleflex LLC$278
  • plus $3K from 33 others

What the payments were for

  • Travel & lodging$6079%
  • Food & beverage$6,43491%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,053 in reported general payments places this provider in the 30th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$694,252
Medicare patients
1,176
Services billed
10,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban224$274,956
OpsumitMacitentan18$228,357
XareltoRivaroxaban74$93,039
EntrestoSacubitril/Valsartan60$73,576
BrilintaTicagrelor47$42,205
JardianceEmpagliflozin26$30,231
FarxigaDapagliflozin Propanediol28$21,825
Repatha SureclickEvolocumab16$21,690
Ranolazine ErRanolazine60$6,160
Flecainide Acetate103$3,561
Midodrine Hcl36$2,990
ClopidogrelClopidogrel Bisulfate282$2,671
Metoprolol Succinate200$2,659
Rosuvastatin Calcium226$2,576
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$2,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$274,956224 claims
Actelion Pharmaceuticals US, Inc.Opsumit$87$228,35718 claims
Johnson & JohnsonXarelto$121$93,03974 claims
NovartisEntresto$173$73,57660 claims
AstraZenecaBrilinta, Farxiga$86$64,03075 claims
Boehringer IngelheimJardiance$45$30,23126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Rock Hill

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →